Reversed phase-high performance liquid chromatographic method to measure migration of semivolatile compound, vanillin, in ipratropium bromide inhalation solution

AAPS PharmSci

Volumn 1, Issue 3, 1999, Pages 1-4

  Conkins, Dennis ^a   Economou, Julia E ^a   Boersma, James A ^a   Dedhiya, Mehendra G ^a   Hansen, Gordon ^b  

^a Roxane Laboratories Inc   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZALDEHYDE DERIVATIVE; BRONCHODILATING AGENT; IPRATROPIUM BROMIDE; VANILLIN;

ARTICLE; CHEMISTRY; DRUG DOSAGE FORM; DRUG PACKAGING; DRUG STORAGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INHALATIONAL DRUG ADMINISTRATION; SENSITIVITY AND SPECIFICITY; SOLUTION AND SOLUBILITY; VOLATILIZATION;

ADMINISTRATION, INHALATION; BENZALDEHYDES; BRONCHODILATOR AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSAGE FORMS; DRUG PACKAGING; DRUG STORAGE; IPRATROPIUM; SENSITIVITY AND SPECIFICITY; SOLUTIONS; VOLATILIZATION;

EID: 53149141394     PISSN: 15221059     EISSN: None     Source Type: Journal    
DOI: 10.1208/ps010315     Document Type: Article

References (11)

1. Rennard SI. Choice of bronchodilator therapy in chronic obstructive pulmonary disease. Respirology. 1997;2:11-15.
2. Product information. ATROVENT® (ipratropium bromide) inhalation solution. In: Physicians' Desk Reference (53 ed.). New Jersey: Medical Economic Company; 1999:743-744.
3. Product information (and package insert). Ipratropium bromide inhalation solution. In: Physicians' Desk Reference (53 ed.). New Jersey: Medical Economic Company; 1999:916.
4. Griffin, RC, Sacharo S. Flexible Packages: Drug and Cosmetic Packaging. New Jersey: Noyes Data Corp.; 1975;169-170.
5. International Conference on Harmonization Quality Guideline III/5442/94-EN. Impurities in New Drug Substances. The Federal Register. 1996;61:372-374.
6. Blume HH, Cartwright AC, and Moeller H. Setting specifications for drug substances and drug products. Drugs Made in Ger. 1996;39:45-50.
7. Guidance for Industry. Container closure systems for packaging of human drugs and biologies, www.fda.gov/cder/guidance/1714fnl.htm. 1999; (see section III).
8. Personal communication. FDA letter. 1999.
9. Product information (and package inserts). Albuterol sulfate inhalation solution and cromolyn sodium inhalation solution In: Physicians' Desk Reference (53 ed.). New Jersey: Medical Economic Company; 1999:916.
10. Carstensen JT. Drug Stability: Principle s and Practices. New York: Marcel Dekker, 1990;301-336.
11. Guidance for Industry. Container closure systems for packaging of human drugs and biologies. http://www.fda.gov/cder/guidance/1714fnl.htm. 1999; (see section III.B.4).